United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?

United Therapeutics Corporation (NASDAQ:UTHR) committed the remaining $477.6 million under its $2 billion authorization to an accelerated share repurchase with Citibank, N.A. on September 8. Earlier transactions included $1.5 billion of accelerated repurchases and $22.4 million of open-market purchases.

The upfront payment was scheduled for around September 10, with initial delivery representing approximately 75% of anticipated shares based on the September 8 closing price. The final share count depends on the average of daily volume-weighted average prices, less a discount and subject to contractual adjustments. Settlement is expected in the fourth quarter of 2026, with additional shares possible or, in limited circumstances, an obligation to pay cash or elect to deliver shares.

Upon completion, United Therapeutics Corporation expects cumulative capital returned to reach approximately $4 billion over roughly two and a half years.

Bull Case

United Therapeutics Corporation reported $3.803 billion of cash, cash equivalents, and marketable investments as of June 30, before the latest repurchase and July acquisition payment.

First-half operating cash flow was $776.9 million, while cash purchases of property, plant and equipment totaled $208.8 million. The $568.1 million difference demonstrates cash generation after those capital purchases, before acquisitions, buybacks and other outflows.

Research investment also continued. Second-quarter research and development expense increased 9% to $146.3 million from $134.0 million. That expense includes noncash stock compensation and contingent-consideration fair-value adjustments, so it differs from cash spending.

United Therapeutics Corporation has FDA reviews pending for ralinepag in pulmonary arterial hypertension and Nebulized Tyvaso in idiopathic pulmonary fibrosis. Ralinepag has a June 24, 2027 target action date; the Nebulized Tyvaso review is expected to finish in late April 2027. Successful approvals and launches could expand earnings across a smaller share base.

Bear Case

The first-half $1.5 billion repurchase exceeded operating cash flow after cash capital purchases. Second-quarter interest income fell to $31.5 million from $51.3 million, primarily because investment securities were sold to fund the March repurchases. Capital return already carries a measurable earnings cost.

United Therapeutics Corporation paid approximately $140 million upfront for Thymmune Therapeutics on July 1, subject to customary purchase-price adjustments. Up to $160 million of additional consideration depends on clinical and regulatory milestones; it represents potential future payments.

United Therapeutics Corporation also budgeted approximately $180 million for facility construction from July 1, 2026 through the end of 2028, to be funded with cash on hand. Projects support inhaled ralinepag manufacturing and animal-organ transplantation. Clinical development, launches, and additional organ facilities create further funding needs.

Commercial pressure reinforces the need for flexibility. Second-quarter revenue declined 2% to $783.3 million, while total Tyvaso revenue fell 4% to $452.6 million. United Therapeutics Corporation attributed adverse sales effects across Nebulized Tyvaso, Tyvaso DPI and Remodulin to competing therapies.

Hedge Fund Sentiment

The filings available so far reflect positions held before United Therapeutics Corporation announced the accelerated share repurchase. Insider Monkey’s database showed 68 hedge funds holding United Therapeutics Corporation at the end of 2Q2026, up from 64 funds three months earlier.

Conclusion

United Therapeutics Corporation has substantial liquidity and continues investing in research and acquisitions. The buyback becomes compelling if commercial cash generation supports the construction program and successful pipeline launches without restricting future investment. Settlement terms, remaining liquidity, and development progress will determine whether capital return strengthens shareholder value.

READ NEXT: Vertiv (VRT) Signed a Deal Worth Up to $2.6B for UtilityInnovation. Can Faster Power Deployment Justify the Contingent Consideration? and Asana (ASAN) Reached a 10% Non-GAAP Operating Margin. Can Agentic Products Restore Expansion? 

This article is originally published at Insider Monkey.